Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab optimization versus ustekinumab after first secondary loss of response to infliximab in Crohn's disease
ChiCTR2300070321Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of infliximab and ustekinumab in Crohn's disease (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Change in IBDQ-32 score at week 24 from baseline. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
infliximabustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2300070321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070321.